Trade Names:Requip- Tablets 0.25 mg- Tablets 0.5 mg- Tablets 1 mg- Tablets 2 mg- Tablets 3 mg- Tablets 4 mg- Tablets 5 mg
Trade Names:Requip XL- Tablets, extended-release 2 mg- Tablets, extended-release 4 mg- Tablets, extended-release 8 mg
Precise mechanism of action in treatment for Parkinson disease unknown; believed to be caused by stimulation of postsynaptic dopamine D 2 -type receptors in the caudate-putamen in the brain.
Mechanism of action as treatment for restless legs syndrome (RLS) is unknown.
T max is 1 to 2 h. High-fat meal increases T max by 2.5 h and reduces C max by 25%, but does not affect extent of absorption. Absolute bioavailability is 55%. Steady state is reached within 2 days.Extended-release
Bioavailability is 45% to 55%. Steady state is reached within 4 days. T max is 6 to 10 h.
Widely distributed; Vd is 7.5 L/kg. Up to 40% protein bound.
Extensively metabolized in liver to inactive metabolites; CYP1A2 is major enzyme involved in metabolism.
Eliminated in urine (less than 10% as unchanged drug). Elimination half-life is approximately 6 h. Cl is 47 L/h.
No difference in pharmacokinetics in patients with moderate renal function impairment compared with patients with CrCl above 50 mL/min. Effect of severe renal function impairment has not been studied.Hepatic Function Impairment
Pharmacokinetics have not been evaluated.Elderly
In patients older than 65 yr of age receiving immediate-release or extended-release formulations, oral Cl is reduced by approximately 30% or 15%, respectively, compared with younger patients. However, dosage adjustment is not necessary.Cigarette smoking
Smoking is expected to increase the Cl of ropinirole because CYP1A2 is known to be induced by smoking. C max was 30% and AUC was 38% lower in smokers compared with nonsmokers.
Treatment of the signs and symptoms of idiopathic Parkinson disease; treatment of moderate to severe primary RLS (immediate-release only).
Individualize by careful titration.Adults Immediate-release
PO 0.25 mg 3 times daily initially. Based on response, dosage may be increased weekly by 0.25 mg/day up to 3 mg/day, then by 1.5 mg/day up to 9 mg/day, then by 3 mg/day to total dose of 24 mg/day.Extended-release
PO Start with 2 mg once daily for 1 to 2 wk, followed by increases of 2 mg/day at 1-wk intervals as appropriate, depending on therapeutic response and tolerability (max, 24 mg/day). Patients may be switched directly from immediate-release. The initial dose of the ER formulation should most closely match the total daily dose of the immediate-release formulation. Following conversion, the dose may be adjusted depending on therapeutic response and tolerability.RLSAdults
PO 0.25 mg once daily 1 to 3 h before bedtime. After 2 days, dose may be increased to 0.5 mg once daily, then to 1 mg once daily at end of first wk; dose may then be increased in 0.5 mg/day increments weekly for 5 additional wk, and then by 1 mg/day after 6 wk (max, 4 mg once daily).
Store at controlled room temperature (68° to 77°F). Protect from light and moisture.ER
Store at 59° to 86°F. Protect from light.
Use with caution because of additive CNS effects.CYP1A2 inducers (eg, cigarette smoking, rifampin)
May increase metabolic Cl of ropinirole.CYP1A2 inhibitors (eg, ciprofloxacin, erythromycin, fluvoxamine)
May decrease metabolic Cl of ropinirole.Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazines, thioxanthenes)
May reduce effectiveness of ropinirole.Estrogen
May reduce Cl of ropinirole.Levodopa
Ropinirole mat potentiate dopaminergic adverse reactions of levodopa, and may cause or exacerbate preexisting dyskinesias.Warfarin
An increase in INR was reported in a patient stabilized on warfarin 9 days after starting ropinirole.
None well documented.
Syncope (12%); orthostatic hypotension (6%); hypertension (5%); palpitation, peripheral ischemia (3%); atrial fibrillation, extrasystole, hypotension, tachycardia (2%); bradycardia, hot flush (at least 1%).
Dizziness, somnolence (40%); dyskinesia (34%); headache (17%); fatigue (11%); hallucinations (10%); confusion (9%); anxiety, asthenia, tremor (6%); amnesia, hypokinesia, nervousness, paresthesia (5%); hypesthesia, vertigo (4%); abnormal dreaming, malaise, paresis, yawning (3%); hyperkinesia, impaired concentration (2%); aggravated Parkinsonism, depression, dystonia, hypoesthesia, insomnia, irritability, migraine, neuralgia, sleep disorder (at least 1%); impulse control symptoms, increased libido including hypersexuality, pathological gambling (postmarketing).
Increased sweating (7%); flushing (3%); night sweats, rash (at least 1%).
Nasopharyngitis (9%); abnormal vision, pharyngitis (6%); rhinitis (4%); eye abnormality (3%); diplopia, nasal congestion, xerophthalmia (2%); pharyngolaryngeal pain (at least 1%).
Nausea (60%); vomiting (12%); dyspepsia (10%); abdominal pain (9%); abdominal pain/discomfort, constipation (6%); diarrhea, dry mouth (5%); anorexia (4%); upper abdominal pain, flatulence (3%); dysphagia, increased salivation (2%); gastroenteritis, gastroesophageal reflux disease, gingivitis, stomach discomfort, tooth abscess, tooth ache, viral gastroenteritis (at least 1%).
UTI (6%); impotence (3%); pyuria, urinary incontinence (2%); erectile dysfunction, hematuria (at least 1%).
Increased alkaline phosphatase (3%); weight decrease (2%); hyperglycemia, increased BUN (at least 1%).
Arthralgia (7%); arthritis, back pain, extremity pain, muscle cramp (3%); RLS (at least 2%); arthrosis, leg cramp, muscle spasm, muscle stiffness, myalgia, neck pain, osteoarthritis, rigors, tendonitis (at least 1%).
Upper respiratory tract infection (9%); sinusitis (4%); bronchitis, cough, dyspnea (3%); asthma, lower respiratory tract infection (at least 1%).
Viral infection (11%); falls (10%); pain (8%); increased drug level, leg edema (7%); dependent edema (6%); chest pain, peripheral edema (4%); hyperhidrosis, influenza (3%); anemia (2%); basal cell carcinoma, gout, influenza-like illness (at least 1%).
Category C .
Safety and efficacy not established.
Incidence of hallucinations appears to be increased with age.
Titrate ropinirole with caution in patients with hepatic function impairment.
Treatment of RLS can result in rebound (worsening of symptoms in early morning hours) and/or augmentation (earlier onset of symptoms in evening or afternoon, increase in symptoms, and spread of symptoms to involve other extremities).
Use with caution in patients with severe CV disease.
Falling asleep during activities of daily living, including driving, has been reported. Consider discontinuation of therapy in patients who develop significant daytime sleepiness or episodes of falling asleep during activities that require active participation (eg, conversations, eating). If therapy is continued in such patients, caution patients not to drive and to avoid other potentially hazardous activities.
A small number of cases of possible fibrotic complications, including cardiac valvulopathy, interstitial lung disease, pleural effusion, and pleural fibrosis, have been reported.
Can occur during ropinirole therapy.
Postural hypotension may occur, especially during dose escalation.
Impulse control symptoms, including compulsive behavior, such as pathological gambling and hypersexuality, have been reported.
Major psychotic disorders may be exacerbated.
Patients with Parkinson disease have a higher risk of developing melanoma than the general population.
Syncope, sometimes associated with bradycardia, has been observed. Most events occur more than 4 wk after starting therapy and are usually associated with a recent increase in dose.
Agitation, asthenia, chest pain, chorea, claustrophobia, confusional state, dizziness, dyskinesia, fatigue, hyperhidrosis, increased coughing, nausea, nightmares, orthostatic hypotension, palpitation, somnolence, syncope, vasovagal syncope, visual hallucinations, vomiting.
Copyright © 2009 Wolters Kluwer Health.